Matches in Nanopublications for { <http://www.w3.org/1999/02/22-rdf-syntax-ns#OBJECT> ?p ?o ?g. }
- OBJECT label "the effects of tocilizumab on COVID 19" assertion.
- OBJECT label "as controls" assertion.
- OBJECT label "between Sub cohorts logrank test" assertion.
- OBJECT label "be matched with an equivalent number of control patients" assertion.
- OBJECT label "with an equivalent number of control patients" assertion.
- OBJECT label "to assess the efficacy and safety of tocilizumab combined with favipiravir in patients with COVID 19" assertion.
- OBJECT label "the efficacy and safety of tocilizumab combined with favipiravir in patients with COVID 19" assertion.
- OBJECT label "to be reliable drugs for the treatment of COVID 19 with elevated IL 6" assertion.
- OBJECT label "to a 14 day combination of favipiravir combined" assertion.
- OBJECT label "significantly higher" assertion.
- OBJECT label "to the favipiravir group" assertion.
- OBJECT label "to tocilizumabtocilizumab" assertion.
- OBJECT label "recruited" assertion.
- OBJECT label " 3 1 1 " assertion.
- OBJECT label "a multicenter trial in adults with COVID 19" assertion.
- OBJECT label "no significant difference between a 14 day combination of favipiravir combined with tocilizumab combination group favipiravir and tocilizumab and tocilizumab tocilizumab P 0 575 HR 1 28 95 CI 0 39 to 4 23 " assertion.
- OBJECT label "the cumulative lung lesion remission rate lung CT examination indicated absorption of lung inflammation " assertion.
- OBJECT label "the pulmonary inflammation of COVID 19 patients" assertion.
- OBJECT label "the deterioration of COVID 19" assertion.
- OBJECT label "reliable drugs for the treatment of COVID 19 with elevated IL 6" assertion.
- OBJECT label "absorption of lung inflammation " assertion.
- OBJECT label "with favipiravir in patients" assertion.
- OBJECT label "Since December 2019" assertion.
- OBJECT label "affect the antibody response against SARS CoV 2" assertion.
- OBJECT label "the antibody response against SARS CoV 2" assertion.
- OBJECT label "the antibody response against SARS CoV 2" assertion.
- OBJECT label "to COVID 19 follow up unit" assertion.
- OBJECT label "8 patient groups" assertion.
- OBJECT label "to analyze variables affecting the humoral response to SARS CoV 2" assertion.
- OBJECT label "variables affecting the humoral response to SARS CoV 2" assertion.
- OBJECT label "with antibody positivity" assertion.
- OBJECT label "a linear relationship with the extent of lung involvement on CT" assertion.
- OBJECT label "the extent of pulmonary involvement on CT" assertion.
- OBJECT label "a factor affecting the antibody response" assertion.
- OBJECT label "the antibody response" assertion.
- OBJECT label "from COVID 19" assertion.
- OBJECT label "in this prospective cohort study" assertion.
- OBJECT label "the humoral response to SARS CoV 2" assertion.
- OBJECT label "Anti S IgG antibodies" assertion.
- OBJECT label "to understand more about the real molecular mechanism of activity of Tocilizumab a humanized monoclonal antibody" assertion.
- OBJECT label "more about the real molecular mechanism of activity of Tocilizumab a humanized monoclonal antibody" assertion.
- OBJECT label "to understand that how Tocilizumab a humanized monoclonal antibody is bound with mIL 6R or sIL 6R " assertion.
- OBJECT label "more therapeutic molecules for this COVID 19 outbreak" assertion.
- OBJECT label "to bind both mIL 6R membrane bound receptor for IL 6 and sIL 6R soluble receptor for IL 6 and inhibit the JAK STAT pathway" assertion.
- OBJECT label "with a high level of release of cytokine in the patients which is known as CRS cytokine release syndrome or cytokine storm syndrome" assertion.
- OBJECT label "both mIL 6R membrane bound receptor for IL 6 and sIL 6R soluble receptor for IL 6 and inhibit the JAK STAT pathway" assertion.
- OBJECT label "that how Tocilizumab a humanized monoclonal antibody is bound with mIL 6R or sIL 6R " assertion.
- OBJECT label "the JAK STAT pathway" assertion.
- OBJECT label "as CRS cytokine release" assertion.
- OBJECT label "a type of pro inflammatory cytokine which release in the severe COVID 19 patients" assertion.
- OBJECT label "storm syndrome" assertion.
- OBJECT label "the cytokine storm syndrome" assertion.
- OBJECT label "immunosuppressive properties" assertion.
- OBJECT label "by copyright" assertion.
- OBJECT label "since tocilizumab s widespread use may result in higher rate of ICU admission and longer mean hospital stay without differences in mortality rate and potentially adverse events" assertion.
- OBJECT label "in higher rate of ICU admission and longer mean hospital stay without differences in mortality rate and potentially adverse events" assertion.
- OBJECT label "in higher rate of ICU admission and longer mean hospital" assertion.
- OBJECT label "with better clinical outcomes" assertion.
- OBJECT label "for clinical trial scenario" assertion.
- OBJECT label "to" assertion.
- OBJECT label "excessive hyper inflammation and death in COVID 19 related pneumonia" assertion.
- OBJECT label "with adverse events" assertion.
- OBJECT label "four randomized controlled trials ( RCTs , with another longer-term follow-up of one RCT ) and 63 observational studies" provenance.
- OBJECT label "four randomized controlled trials ( RCTs , with another longer-term follow-up of one RCT ) and 63 observational studies" provenance.
- OBJECT label "four randomized controlled trials ( RCTs , with another longer-term follow-up of one RCT ) and 63 observational studies" provenance.
- OBJECT label "four randomized controlled trials ( RCTs , with another longer-term follow-up of one RCT ) and 63 observational studies" provenance.
- OBJECT label "four randomized controlled trials ( RCTs , with another longer-term follow-up of one RCT ) and 63 observational studies" provenance.
- OBJECT label "four randomized controlled trials ( RCTs , with another longer-term follow-up of one RCT ) and 63 observational studies" provenance.
- OBJECT label "four randomized controlled trials ( RCTs , with another longer-term follow-up of one RCT ) and 63 observational studies" provenance.
- OBJECT label "four randomized controlled trials ( RCTs , with another longer-term follow-up of one RCT ) and 63 observational studies" provenance.
- OBJECT label "four randomized controlled trials ( RCTs , with another longer-term follow-up of one RCT ) and 63 observational studies" provenance.
- OBJECT label "four randomized controlled trials ( RCTs , with another longer-term follow-up of one RCT ) and 63 observational studies" provenance.
- OBJECT label "four randomized controlled trials ( RCTs , with another longer-term follow-up of one RCT ) and 63 observational studies" provenance.
- OBJECT label "four randomized controlled trials ( RCTs , with another longer-term follow-up of one RCT ) and 63 observational studies" provenance.
- OBJECT label "four randomized controlled trials ( RCTs , with another longer-term follow-up of one RCT ) and 63 observational studies" provenance.
- OBJECT label "four randomized controlled trials ( RCTs , with another longer-term follow-up of one RCT ) and 63 observational studies" provenance.
- OBJECT label "four randomized controlled trials ( RCTs , with another longer-term follow-up of one RCT ) and 63 observational studies" provenance.
- OBJECT label "four randomized controlled trials ( RCTs , with another longer-term follow-up of one RCT ) and 63 observational studies" provenance.
- OBJECT label "four randomized controlled trials ( RCTs , with another longer-term follow-up of one RCT ) and 63 observational studies" provenance.
- OBJECT label "four randomized controlled trials ( RCTs , with another longer-term follow-up of one RCT ) and 63 observational studies" provenance.
- OBJECT label "four randomized controlled trials ( RCTs , with another longer-term follow-up of one RCT ) and 63 observational studies" provenance.
- OBJECT label "four randomized controlled trials ( RCTs , with another longer-term follow-up of one RCT ) and 63 observational studies" provenance.
- OBJECT label "four randomized controlled trials ( RCTs , with another longer-term follow-up of one RCT ) and 63 observational studies" provenance.
- OBJECT label "four randomized controlled trials ( RCTs , with another longer-term follow-up of one RCT ) and 63 observational studies" provenance.
- OBJECT label "four randomized controlled trials ( RCTs , with another longer-term follow-up of one RCT ) and 63 observational studies" provenance.
- OBJECT label "four randomized controlled trials ( RCTs , with another longer-term follow-up of one RCT ) and 63 observational studies" provenance.
- OBJECT label "four randomized controlled trials ( RCTs , with another longer-term follow-up of one RCT ) and 63 observational studies" provenance.
- OBJECT label "four randomized controlled trials ( RCTs , with another longer-term follow-up of one RCT ) and 63 observational studies" provenance.
- OBJECT label "four randomized controlled trials ( RCTs , with another longer-term follow-up of one RCT ) and 63 observational studies" provenance.
- OBJECT label "four randomized controlled trials ( RCTs , with another longer-term follow-up of one RCT ) and 63 observational studies" provenance.
- OBJECT label "four randomized controlled trials ( RCTs , with another longer-term follow-up of one RCT ) and 63 observational studies" provenance.
- OBJECT label "four randomized controlled trials ( RCTs , with another longer-term follow-up of one RCT ) and 63 observational studies" provenance.
- OBJECT label "four randomized controlled trials ( RCTs , with another longer-term follow-up of one RCT ) and 63 observational studies" provenance.
- OBJECT label "four randomized controlled trials ( RCTs , with another longer-term follow-up of one RCT ) and 63 observational studies" provenance.
- OBJECT label "four randomized controlled trials ( RCTs , with another longer-term follow-up of one RCT ) and 63 observational studies" provenance.
- OBJECT label "four randomized controlled trials ( RCTs , with another longer-term follow-up of one RCT ) and 63 observational studies" provenance.
- OBJECT label "four randomized controlled trials ( RCTs , with another longer-term follow-up of one RCT ) and 63 observational studies" provenance.
- OBJECT label "four randomized controlled trials ( RCTs , with another longer-term follow-up of one RCT ) and 63 observational studies" provenance.
- OBJECT label "four randomized controlled trials ( RCTs , with another longer-term follow-up of one RCT ) and 63 observational studies" provenance.
- OBJECT label "four randomized controlled trials ( RCTs , with another longer-term follow-up of one RCT ) and 63 observational studies" provenance.